{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:29:20Z","timestamp":1788262160065,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T00:00:00Z","timestamp":1590451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T00:00:00Z","timestamp":1590451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2020,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In CML, treatment-free remission (TFR) refers to having a stable deep molecular response without the need for ongoing tyrosine kinase inhibitor treatment. Whilst recommendations exist about the technical management of stopping and re-starting therapy, much is still unknown about the experiences of those considering and undertaking TFR. This study sought to obtain the patient perspective, identify areas of unmet needs and create recommendations for improvements. Fifty-six percent of patients reported fear or anxiety during treatment discontinuation, whereas only 7% of patients were asked if they needed psychological support during this period. Where patients re-initiated treatment; 59% felt scared or anxious, and 56% felt depressed. Twenty-six percent of re-initiated patients received psychological and\/or emotional support at this time. Sixty percent of patients experienced withdrawal symptoms whilst discontinuing treatment, however, 40% of patients who experienced withdrawal symptoms reported that they were not fully supported by their doctor in managing all the symptoms. Healthcare professionals should further consider how they monitor the psychological well-being of patients who are discontinuing or re-initiating treatment, and review what support is offered in response to identified concerns. Surveillance of withdrawal symptoms should be a priority during treatment discontinuation, along with how healthcare professionals assist in the management of these.<\/jats:p>","DOI":"10.1038\/s41375-020-0867-0","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T13:03:06Z","timestamp":1590498186000},"page":"2102-2112","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs"],"prefix":"10.1038","volume":"34","author":[{"given":"Giora","family":"Sharf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7355-5571","authenticated-orcid":false,"given":"Jennifer A.","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zack","family":"Pemberton-Whiteley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Bombaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita I. O.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahija","family":"Gouimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel B.","family":"Deekes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Daban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Geissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,26]]},"reference":[{"key":"867_CR1","doi-asserted-by":"crossref","unstructured":"Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105:2640\u201353.","DOI":"10.1182\/blood-2004-08-3097"},{"key":"867_CR2","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","volume":"103","author":"C Gambacorti-Passerini","year":"2011","unstructured":"Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011;103:553\u201361.","journal-title":"J Natl Cancer Inst"},{"key":"867_CR3","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","volume":"29","author":"M Bj\u00f6rkholm","year":"2011","unstructured":"Bj\u00f6rkholm M, Ohm L, Eloranta S, Derolf \u00c5, Hultcrantz M, Sj\u00f6berg J, et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol. 2011;29:2514\u201320.","journal-title":"J Clin Oncol"},{"key":"867_CR4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","volume":"32","author":"R Hehlmann","year":"2013","unstructured":"Hehlmann R, M\u00fcller M, Lauseker M, Hanfstein B, Fabarius A, Schreiber, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose Imatinib: results from the randomized CML-study IV. J Clin Oncol. 2013;32:415\u201323.","journal-title":"J Clin Oncol"},{"key":"867_CR5","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/leu.2015.152","volume":"29","author":"F Castagnetti","year":"2015","unstructured":"Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F, et al. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. Leukemia. 2015;29:1823\u201331.","journal-title":"Leukemia"},{"key":"867_CR6","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","volume":"118","author":"F Efficace","year":"2011","unstructured":"Efficace F, Baccaran M, Breccia M, Alimena G, Rosti G, Cottone F, et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood. 2011;118:4554\u201360.","journal-title":"Blood"},{"key":"867_CR7","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in philadelphia chromosome\u2013positive leukemias. N. Engl J Med. 2013;369:1783\u201396.","journal-title":"N. Engl J Med"},{"key":"867_CR8","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl J Med. 2010;362:2251\u20139.","journal-title":"N. Engl J Med"},{"key":"867_CR9","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl J Med. 2006;355:2408\u201317.","journal-title":"N. Engl J Med"},{"key":"867_CR10","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","volume":"29","author":"L Kalmanti","year":"2015","unstructured":"Kalmanti L, Saussele S, Lauseker M, M\u00fcller MC, DietzC T, Heinrich L, et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. 5. Leukemia. 2015;29:1123\u201332.","journal-title":"Leukemia"},{"key":"867_CR11","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/leu.2013.70","volume":"27","author":"TD Kim","year":"2013","unstructured":"Kim TD, Rea D, Schwarz M, Grille P, Nicolini FE, Rosti G, et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia. 2013;27:1316\u201321.","journal-title":"Leukemia"},{"key":"867_CR12","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/asheducation-2011.1.128","volume":"2011","author":"A Hochhaus","year":"2011","unstructured":"Hochhaus A. Educational session: managing chronic myeloid leukemia as a chronic disease. Hematol Am Soc Hematol Educ Program. 2011;2011:128\u201335.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"867_CR13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1744-8603-5-19","volume":"5","author":"P Kanavos","year":"2009","unstructured":"Kanavos P, Vandoros S, Garcia-Gonzale P. Benefits of global partnerships to facilitate access to medicines in developing countries: a multi-country analysis of patients and patient outcomes in GIPAP. Glob Health. 2009;5:19.","journal-title":"Glob Health"},{"key":"867_CR14","unstructured":"National Comprehensive Cancer Network. Chronic Myelogenous Leukemia. NCCN Clinical Practice Guidelines in Oncology Version 2.2020. National Comprehensive Cancer Network, 2020:45\u20136."},{"key":"867_CR15","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","volume":"109","author":"P Rousselot","year":"2006","unstructured":"Rousselot P, Huguet F, Rea D, Legros L, Cayuel JM, Maarek O, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood. 2006;109:58\u201360.","journal-title":"Blood."},{"key":"867_CR16","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, R\u00e9a D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029\u201335.","journal-title":"Lancet Oncol"},{"key":"867_CR17","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122:515\u201322.","journal-title":"Blood"},{"key":"867_CR18","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3324\/haematol.2011.056853","volume":"97","author":"N Takahashi","year":"2012","unstructured":"Takahashi N, Taiichi K, Maeda Y, Sugihara T, Usuki K, Kawaguchi T, et al. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica. 2012;97:903\u20136.","journal-title":"Haematologica"},{"key":"867_CR19","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1182\/blood.V122.21.381.381","volume":"122","author":"P Rousselot","year":"2013","unstructured":"Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet BR, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. Blood. 2013;122:381.","journal-title":"Blood."},{"key":"867_CR20","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ajh.24120","volume":"90","author":"S Mori","year":"2015","unstructured":"Mori S, Vagge E, le Coutre P, Abruzzese E, Martino B, Pungolino E, et al. Age and PCR can predict relapse in CML patients who discontinued imatinib: The ISAV study. Am J Hematol. 2015;90:910\u20134.","journal-title":"Am J Hematol"},{"key":"867_CR21","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3324\/haematol.2015.139899","volume":"101","author":"SE Lee","year":"2016","unstructured":"Lee SE, Choi SY, Song HY, Kim SH, Choi MY, Park JS, et al. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica. 2016;101:717\u201323.","journal-title":"Haematologica"},{"key":"867_CR22","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/bjh.13983","volume":"176","author":"D Ferrero","year":"2017","unstructured":"Ferrero D, Cerrano M, Cris\u00e0 E, Aguzzi C, Giai V, Boccadoro M. How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience. Br J Haematol. 2017;176:669\u201371.","journal-title":"Br J Haematol"},{"key":"867_CR23","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19:747\u201357.","journal-title":"Lancet Oncol"},{"key":"867_CR24","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-018-0125-0","volume":"8","author":"JC Hern\u00e1ndez-Boluda","year":"2018","unstructured":"Hern\u00e1ndez-Boluda JC, Pereira A, Pastor-Gal\u00e1n I, Alvarez-Larr\u00e1n A, Savchuk A, Puerta JM, et al. Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients. Blood Cancer J. 2018;8:91.","journal-title":"Blood Cancer J"},{"key":"867_CR25","volume":"18","author":"N Cerveira","year":"2018","unstructured":"Cerveira N, Loureiro B, Bizarro S, Correia C, Torres L, Lisboa S, et al. Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution. BMC Cancer. 2018;18:1245.","journal-title":"BMC Cancer"},{"key":"867_CR26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12185-017-2334-x","volume":"107","author":"N Takahashi","year":"2018","unstructured":"Takahashi N, Tauchi T, Kitamura K, Miyamura K, Saburi Y, Hatta Y, et al. Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study. Int J Hematol. 2018;107:185\u201393.","journal-title":"Int J Hematol"},{"key":"867_CR27","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/16078454.2019.1590964","volume":"24","author":"M Iino","year":"2019","unstructured":"Iino M, Yamamoto T, Sakamoto Y. Outcomes of unplanned tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: retrospective analysis of real-world experience in a single institution. Hematology. 2019;24:355\u201361.","journal-title":"Hematology"},{"key":"867_CR28","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.3324\/haematol.2018.205054","volume":"104","author":"C Fava","year":"2019","unstructured":"Fava C, Rege-Cambrin G, Dogliotti I, Cerrano M, Berchialla P, Dragani M, et al. Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. Haematologica. 2019;104:1589\u201396.","journal-title":"Haematologica"},{"key":"867_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-018-0686-1","volume":"12","author":"K Chamoun","year":"2019","unstructured":"Chamoun K, Kantarjian H, Atallah R, Gonzalez GN, Issa GC, Rios MB, et al. Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. J Hematol Onco. 2019;12:1.","journal-title":"J Hematol Onco"},{"key":"867_CR30","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s10147-018-1368-2","volume":"24","author":"S Fujisawa","year":"2019","unstructured":"Fujisawa S, Ueda Y, Usuki K, Kobayashi H, Kondo E, Doki N, et al. Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial). Int J Clin Onco. 2019;24:445\u201353.","journal-title":"Int J Clin Onco"},{"key":"867_CR31","doi-asserted-by":"crossref","first-page":"6606","DOI":"10.1158\/1078-0432.CCR-18-3373","volume":"25","author":"FE Nicolini","year":"2019","unstructured":"Nicolini FE, Dulucq S, Boureau L, Cony-Makhoul P, Charbonnier A, Escoffre-Barbe M, et al. Evaluation of residual disease and TKI duration are critical predictive factors for molecular recurrence after stopping imatinib first-line in chronic Phase CML patients. Clin Cancer Res. 2019;25:6606\u201313.","journal-title":"Clin Cancer Res"},{"key":"867_CR32","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","volume":"129","author":"D Rea","year":"2017","unstructured":"Rea D, Nicolini FE, Tulliez M, Guilhot F, Guilhot J, Guerci-Bresler A, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. 7. Blood. 2017;129:846\u201354.","journal-title":"Blood"},{"key":"867_CR33","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.clml.2018.03.004","volume":"18","author":"M Okada","year":"2018","unstructured":"Okada M, Imagawa J, Tanaka H, Nakamae H, Hino M, Murai K, et al. Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second-line treatment. Clin Lymphoma Myeloma Leuk. 2018;18:353\u201360.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"867_CR34","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M17-1094","volume":"168","author":"FX Mahon","year":"2018","unstructured":"Mahon FX, Boquimpani C, Kim DW, Benyamini N, Clementino NCD, Shuvaev V, et al. Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single-group, phase 2, open-label study. Ann Intern Med. 2018;168:461\u201370.","journal-title":"Ann Intern Med"},{"key":"867_CR35","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00432-018-2604-x","volume":"144","author":"DM Ross","year":"2018","unstructured":"Ross DM, Masszi T, G\u00f3mez Casares MT, Hellmann A, Stentoft J, Conneally E, et al. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. J Cancer Res Clin Oncol. 2018;144:945\u201354.","journal-title":"J Cancer Res Clin Oncol"},{"key":"867_CR36","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/cas.13430","volume":"109","author":"T Kumagai","year":"2018","unstructured":"Kumagai T, Nakaseko C, Nishiwaki K, Yoshida C, Ohashi K, Takezako N, et al. Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation. Cancer Sci. 2018;109:182\u201392.","journal-title":"Cancer Sci"},{"key":"867_CR37","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3324\/haematol.2018.194894","volume":"103","author":"N Takahashi","year":"2018","unstructured":"Takahashi N, Nishiwaki K, Nakaseko C, Aotsuka N, Sano K, Ohwada C, et al. Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan. Haematologica. 2018;103:1835\u201342.","journal-title":"Haematologica"},{"key":"867_CR38","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood-2012-02-408229","volume":"120","author":"L Legros","year":"2012","unstructured":"Legros L, Rousselot P, Giraudier S, Tulliez M, Huguet F, Nicolini F, et al. Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response. Blood. 2012;120:1959\u201360.","journal-title":"Blood"},{"key":"867_CR39","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1002\/cncr.30885","volume":"123","author":"L Legros","year":"2017","unstructured":"Legros L, Nicolini FE, Etienne G, Rousselot P, Rea D, Giraudier S, et al. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia. Cancer. 2017;123:4403\u201310.","journal-title":"Cancer."},{"key":"867_CR40","first-page":"313","volume":"130","author":"S Saussele","year":"2017","unstructured":"Saussele S, Richter J, Guilhot J, Hjorth-Hansen H, Medina de Almeida A, Janssen JJWM, et al. \u201cDuration of deep molecular response\u201d has most impact on the success of cessation of tyrosine kinase inhibitor treatment in chronic myeloid leukemia - results from the EURO-SKI trial. Blood. 2017;130:313\u2013313.","journal-title":"Blood"},{"key":"867_CR41","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","volume":"128","author":"TP Hughes","year":"2016","unstructured":"Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016;128:17\u201323.","journal-title":"Blood."},{"key":"867_CR42","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1002\/cncr.31411","volume":"124","author":"D Rea","year":"2018","unstructured":"Rea D, Ame S, Berger M, Cayuela JM, Charbonnier A, Coiteux V, et al. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group. Cancer. 2018;124:2956\u201363.","journal-title":"Cancer"},{"key":"867_CR43","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384.","journal-title":"Leukemia"},{"key":"867_CR44","doi-asserted-by":"crossref","first-page":"e241","DOI":"10.3747\/co.21.1736","volume":"21","author":"D Sanford","year":"2014","unstructured":"Sanford D, Kyle R, Lazo-Langner A, Xenocostas A, Chin-Yee I, Howson-Jan K, et al. Patient preferences for stopping tyrosine kinase inhibitors in chronic myeloid leukemia. Curr Onco. 2014;21:e241\u2013e249.","journal-title":"Curr Onco"},{"key":"867_CR45","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1182\/blood.V124.21.4547.4547","volume":"124","author":"CM Boquimpani","year":"2014","unstructured":"Boquimpani CM, Szczudlo T, Mendelson E, Benjamin K, Masszi T. Attitudes and perceptions of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) toward treatment-free remission (TFR). Blood. 2014;124:4547\u20134547.","journal-title":"Blood"},{"key":"867_CR46","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1080\/10428194.2017.1337114","volume":"59","author":"LA Villemagne Sanchez","year":"2018","unstructured":"Villemagne Sanchez LA, O\u2019Callaghan C, Gough K, Hal K, Kashima Y, Seymour JF, et al. Patient perceptions of treatment-free remission in chronic myeloid leukemia. Leuk Lymphoma. 2018;59:406\u201315.","journal-title":"Leuk Lymphoma"},{"key":"867_CR47","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1182\/blood.V126.23.1584.1584","volume":"126","author":"S Goldberg","year":"2015","unstructured":"Goldberg S, Hamarman S. Patients with chronic myelogenous leukemia may not want to discontinue tyrosine kinase inhibitor therapy. Blood. 2015;126:1584\u20131584.","journal-title":"Blood"},{"key":"867_CR48","doi-asserted-by":"crossref","first-page":"e20569","DOI":"10.1200\/jco.2015.33.15_suppl.e20569","volume":"33","author":"J Cho","year":"2017","unstructured":"Cho J, Kang D, Park S, Jeong Eon L, Seok Jin N, Hak Min L, et al. Scanxiety and quality of life among breast cancer survivors. J Clin Oncol. 2017;33:e20569\u2013e20569.","journal-title":"J Clin Oncol"},{"key":"867_CR49","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1007\/s10147-018-1275-6","volume":"23","author":"R Sogawa","year":"2018","unstructured":"Sogawa R, Kimura S, Yakabe R, Mizokami Y, Tasaki M, Sueoka-Aragane N, et al. Anxiety and depression associated with tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia. Int J Clin Onco. 2018;23:974\u20139.","journal-title":"Int J Clin Onco"},{"key":"867_CR50","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.clml.2018.04.005","volume":"18","author":"G Saglio","year":"2018","unstructured":"Saglio G, Sharf G, Almeida A, Bogdanovic A, Bombaci F, \u010cugurovi\u0107 J, et al. Considerations for treatment-free remission in patients with chronic myeloid leukemia: a joint patient\u2013physician perspective. Clin Lymphoma Myeloma Leuk. 2018;18:375\u20139.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"867_CR51","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1200\/JCO.2014.55.6910","volume":"32","author":"J Richter","year":"2014","unstructured":"Richter J, S\u00f6derlund S, L\u00fcbking A, Dreimane A, Lotfi K, Markev\u00e4rn B, et al. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?. J Clin Oncol. 2014;32:2821\u20133.","journal-title":"J Clin Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0867-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0867-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0867-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T13:08:14Z","timestamp":1705064894000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0867-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,26]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8,1]]}},"alternative-id":["867"],"URL":"https:\/\/doi.org\/10.1038\/s41375-020-0867-0","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,26]]},"assertion":[{"value":"6 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"GS reports: consultancy for Leukemia Patient Advocates Foundation, Israeli CML patient organization, Novartis, Incyte, AbbVie, Takeda, Bristol-Myers Squibb, Celgene and Pfizer; advisory board membership for CML Advocates Network, Leukemia Patient Advocates Foundation and Israeli CML patient organization; organizational grant funding from Novartis, Incyte, Amgen, Bristol-Myers Squibb, Celgene, AOP Orphan, CTI, Medison, Roche, Janssen, Pfizer, Takeda and Gilead. CM reports: employment for Leukemia Patient Advocates Foundation; consultancy for Psoriasis en Red and AbbVie; advisory board membership for Psoriasis en Red and FFpaciente; organizational grant funding from AbbVie, Leo Pharma, UCB, Celgene, Pfizer, Novartis Oncology, Incyte, Takeda, Bristol-Myers Squibb, The Leukemia & Lymphoma Society and International CML Foundation. JB reports employment for Quality Health Ltd. ZPW reports: employment for Leukemia Care; equity ownership of Patient Evidence; consultancy for Acute Leukemia Advocates Network, Amgen, Bristol-Myers Squibb, Celgene, Incyte, Janssen, Novartis and Pfizer; advisory board membership for Acute Leukemia Advocates Network and CML Advocates Network; speakers bureau for Amgen, Bristol-Myers Squibb, Gilead, Jazz, Novartis and Pfizer; organizational grant funding from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Gilead, Incyte, Jazz, Janssen, Kyowa Kirin, Novartis and Takeda. FB reports: consultancy for Abbvie, Bristol-Myers Squibb, Celgene, Jazz, Novartis, Takeda; board membership of AIL Torino onlus, CML Advocates Network, CLL Advocates Network, MPN Advocates Network; organizational grant funding from Abbvie, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Gilead, Janssen, Novartis, Pfizer, Roche, Takeda. ROC reports: consultancy for LYLE (patient organization for Lymphoma, Leukemia & MDS), Autisme 4700 DK, Bristol-Myers Squibb, Incyte, Janssen, Novartis Nordic, Roche and Takeda; board membership of LYLE and Autisme 4700 DK; organizational grant funding from Abbvie, Gilead, Incyte, Janssen, Novartis Nordic, Pfizer, Roche and Takeda. BG reports: consultancy for Bristol-Myers Squibb, Incyte, Novartis, Takeda and Pfizer; board membership of AMAL (Association des malades atteints de leuc\u00e9mies); organizational grant funding from Novartis. ND reports Honoraria from Novartis. MD reports no competing interests. JG reports: consultancy for AMGEN, Bristol-Myers Squibb, Bayer, Biomarin, Gr\u00fcnenthal, Janssen, Novartis, Pfizer, Roche, Servier, Takeda and UCB; board membership of CML Advocates Network, Leukemia Patient Advocates Foundation and LeukaNET; contributions to IMI-funded consortium projects HARMONY and EUPATI by EFPIA companies; organizational grant funding from Incyte, Novartis, Pfizer, Bristol-Myers Squibb and Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}